A specific monoclonal anti-HER3 antibody, patritumab, was labeled with 64Cu and its safety, dosimetry, and binding were assessed in a group of patients with advance solid tumors including breast cancer [38]. The gene discussed is ERBB3; the disease is breast cancer.